Vietnam’s Human Organoids Market Emerges as a New Frontier for Drug Discovery and Precision Medicine

Vietnam’s rapidly developing biotechnology sector is opening opportunities in one of the most advanced areas of life-science research: human organoids.

Human organoids are three-dimensional, self-organising cell cultures derived from stem cells or patient tissue that reproduce some of the structural and functional characteristics of human organs. Sometimes described as “mini-organs”, they provide researchers with more physiologically relevant models for studying human biology, disease progression and response to treatment than conventional two-dimensional cell cultures.

Their applications increasingly extend across drug discovery, toxicity testing, disease modelling, regenerative medicine, cancer research and personalised medicine.

While no reliable publicly disclosed figure is currently available for Vietnam's standalone human organoids market, dedicated market research confirms that a commercial organoids market is developing in the country. A reasonable current estimate places the Vietnamese market at approximately US$2–4 million in 2025, potentially rising to around US$6–12 million by 2030.

These figures should be viewed as market estimates rather than published country-level values. However, the direction of travel is supported by strong regional and global growth.

A rapidly expanding Asia-Pacific market

Asia-Pacific is emerging as one of the world's fastest-growing regions for organoid technology.

Grand View Research values the Asia-Pacific human organoids market at US$140.5 million in 2024 and forecasts it to reach US$494.1 million by 2030.

Globally, the market is also expanding rapidly. Fortune Business Insights values the human organoids market at US$1.18 billion in 2025 and expects it to reach US$5.71 billion by 2034, with drug discovery and development expected to account for a particularly significant proportion of demand.

The growth reflects an important change in pharmaceutical and biomedical research: the search for experimental models that reproduce human biology more accurately.

From laboratory research to drug development

Traditional cell cultures remain fundamental to biomedical research, but they cannot always reproduce the complex interactions taking place within human tissues. Animal models provide greater biological complexity but can produce results that do not translate directly to patients.

Organoids provide another option.

Researchers can create models resembling the brain, liver, kidney, intestine, lung, pancreas and other organs, enabling biological processes and disease pathways to be studied under controlled laboratory conditions.

Patient-derived tumour organoids are particularly interesting for oncology research. Because they can retain some of the biological characteristics of an individual tumour, researchers can potentially expose the organoid to different therapies and investigate how the patient's cancer might respond.

This is contributing to interest in organoids as an enabling technology for precision and personalised medicine.

Vietnam’s biotechnology ecosystem creates a platform for growth

Organoids remain a small and specialist segment of Vietnam's healthcare economy, but they sit within a much larger biotechnology market.

Vietnam's biotechnology sector was valued at approximately US$3.4 billion in 2025 and is forecast to approach US$8.9 billion by 2034. Growth is being supported by expanding healthcare research, molecular diagnostics, genomics, cell-based technologies, tissue engineering and increasing demand for more personalised approaches to medicine.

Government policy is also supportive of biotechnology development.

Vietnam has set an ambition to become one of Asia's leading biotechnology economies, with policies specifically encouraging research into stem-cell technology, gene technology, pharmaceuticals, vaccines and biological medicines.

This creates a supportive environment for the longer-term development of organoid research capabilities.

Where the commercial opportunities lie

The immediate opportunity in Vietnam is unlikely to be large-scale clinical use of organoids. Instead, demand is more likely to develop initially around the research infrastructure required to create and analyse them.

That creates opportunities for suppliers of 3D cell-culture systems, stem cells, extracellular matrices, culture media, reagents, growth factors, laboratory automation, imaging systems, microscopy, sequencing technologies and analytical software.

Companies supplying research laboratories may find increasing crossover between organoids and adjacent technologies including genomics, proteomics, single-cell analysis, spatial biology and high-content imaging.

Pharmaceutical and biotechnology companies represent another important potential customer group.

As Vietnam strengthens its domestic pharmaceutical and biopharmaceutical capabilities, more sophisticated preclinical research tools will be required to support drug screening, efficacy studies and toxicology programmes. Organoid models have the potential to become part of that infrastructure.

CROs, universities, academic institutes and specialist biomedical research centres are also likely to drive adoption.

Cancer research could accelerate adoption

Oncology represents one of the most promising applications.

Tumour-derived organoids allow researchers to investigate tumour biology, resistance mechanisms and therapeutic response while preserving important characteristics of the original cancer.

As Vietnam expands its capabilities in cancer diagnostics, molecular testing, genomics and precision medicine, organoids could increasingly complement technologies such as next-generation sequencing and biomarker analysis.

Other potential research areas include gastrointestinal disease, neurological disorders, liver disease, infectious disease and regenerative medicine.

A specialist market with significant growth potential

Vietnam's human organoids market remains at an early stage compared with established research markets such as the United States, China, Japan and South Korea.

That is precisely what makes it commercially interesting.

Rather than representing a mature consumables market, organoids form part of a broader shift towards advanced life-science research, human-relevant disease models and precision drug development.

For international suppliers, the opportunity extends beyond organoid models themselves. It includes the complete ecosystem required to support organoid research—from cell culture and reagents to automation, imaging, genomics and data analysis.

As Vietnam invests further in biotechnology, pharmaceutical R&D and biomedical research infrastructure, organoids could become an increasingly important part of the country's life-science landscape.

For companies operating across cell biology, stem cells, 3D culture, laboratory automation, imaging, genomics, drug discovery and preclinical research, Vietnam therefore represents an emerging market worth watching.

READ THE FULL INSIGHTS REPORT